Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
A Phase 1/2a Dose-escalation Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Multiple Intravenous (IV) Infusions Alone and in Combination With Irinotecan in Patients With Metastatic, Refractory Colorectal Carcinoma.
Status: Enrolling
Updated:  1/6/2016
Billings Clinic Cancer Center
mi
from
Billings, MT
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
A Phase 1/2a Dose-escalation Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Multiple Intravenous (IV) Infusions Alone and in Combination With Irinotecan in Patients With Metastatic, Refractory Colorectal Carcinoma.
Status: Enrolling
Updated: 1/6/2016
Billings Clinic Cancer Center
mi
from
Billings, MT
Click here to add this to my saved trials
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
A Phase 1/2a Dose-escalation Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Multiple Intravenous (IV) Infusions Alone and in Combination With Irinotecan in Patients With Metastatic, Refractory Colorectal Carcinoma.
Status: Enrolling
Updated:  1/6/2016
Univ of North Carolina
mi
from
Chapel Hill, NC
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
A Phase 1/2a Dose-escalation Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Multiple Intravenous (IV) Infusions Alone and in Combination With Irinotecan in Patients With Metastatic, Refractory Colorectal Carcinoma.
Status: Enrolling
Updated: 1/6/2016
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
A Phase 1/2a Dose-escalation Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Multiple Intravenous (IV) Infusions Alone and in Combination With Irinotecan in Patients With Metastatic, Refractory Colorectal Carcinoma.
Status: Enrolling
Updated:  1/6/2016
Gabrail Cancer Center
mi
from
Canton, OH
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
A Phase 1/2a Dose-escalation Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Multiple Intravenous (IV) Infusions Alone and in Combination With Irinotecan in Patients With Metastatic, Refractory Colorectal Carcinoma.
Status: Enrolling
Updated: 1/6/2016
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
A Phase 1/2a Dose-escalation Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Multiple Intravenous (IV) Infusions Alone and in Combination With Irinotecan in Patients With Metastatic, Refractory Colorectal Carcinoma.
Status: Enrolling
Updated:  1/6/2016
Ohio State University
mi
from
Columbus, OH
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
A Phase 1/2a Dose-escalation Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Multiple Intravenous (IV) Infusions Alone and in Combination With Irinotecan in Patients With Metastatic, Refractory Colorectal Carcinoma.
Status: Enrolling
Updated: 1/6/2016
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
A Phase 1/2a Dose-escalation Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Multiple Intravenous (IV) Infusions Alone and in Combination With Irinotecan in Patients With Metastatic, Refractory Colorectal Carcinoma.
Status: Enrolling
Updated:  1/6/2016
Mayo Clinic
mi
from
Scottsdale, AZ
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
A Phase 1/2a Dose-escalation Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Multiple Intravenous (IV) Infusions Alone and in Combination With Irinotecan in Patients With Metastatic, Refractory Colorectal Carcinoma.
Status: Enrolling
Updated: 1/6/2016
Mayo Clinic
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
A Phase 1/2a Dose-escalation Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Multiple Intravenous (IV) Infusions Alone and in Combination With Irinotecan in Patients With Metastatic, Refractory Colorectal Carcinoma.
Status: Enrolling
Updated:  1/6/2016
Juravinski Cancer Centre
mi
from
Hamilton,
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
A Phase 1/2a Dose-escalation Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Multiple Intravenous (IV) Infusions Alone and in Combination With Irinotecan in Patients With Metastatic, Refractory Colorectal Carcinoma.
Status: Enrolling
Updated: 1/6/2016
Juravinski Cancer Centre
mi
from
Hamilton,
Click here to add this to my saved trials
Right-sided Retroflexion With Standard Adult Versus Pediatric Colonoscopes
Right-sided Retroflexion With Standard Adult Versus Pediatric Colonoscopes
Status: Enrolling
Updated:  1/6/2016
Froedtert Surgery Center
mi
from
Milwaukee, WI
Right-sided Retroflexion With Standard Adult Versus Pediatric Colonoscopes
Right-sided Retroflexion With Standard Adult Versus Pediatric Colonoscopes
Status: Enrolling
Updated: 1/6/2016
Froedtert Surgery Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Birmingham, AL
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Little Rock, AR
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Bellflower, CA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Bellflower, CA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Duarte, CA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Duarte, CA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Fountain Valley, CA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Fresno, CA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Fresno, CA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Hayward, CA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Hayward, CA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Oakland, CA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Oakland, CA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Pleasant Hill, CA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Pleasant Hill, CA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Roseville, CA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Roseville, CA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Sacramento, CA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Sacramento, CA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
San Francisco, CA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
San Francisco, CA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
San Jose, CA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
San Jose, CA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Santa Clara, CA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
South San Francisco, CA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
South San Francisco, CA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Vallejo, CA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Vallejo, CA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Walnut Creek, CA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Denver, CO
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Stamford, CT
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Stamford, CT
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Trumbull, CT
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Trumbull, CT
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Hollywood, FL
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Hollywood, FL
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Jacksonville, FL
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Miami, FL
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Port Saint Lucie, FL
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Port Saint Lucie, FL
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Boise, ID
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Boise, ID
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Joliet, IL
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Joliet, IL
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Maywood, IL
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Maywood, IL
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Peoria, IL
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Peoria, IL
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Goshen, IN
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Goshen, IN
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Terre Haute, IN
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Terre Haute, IN
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Fairway, KA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Fairway, KA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Scarborough, ME
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Scarborough, ME
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Burlington, MA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Burlington, MA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Billings, MT
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Billings, MT
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Lincoln, NE
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Cherry Hill, NJ
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Albuquerque, NM
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Albuquerque, NM
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials